Fei Wang
Research Subjects
Fei Wang has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Chongshen Guo
School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, 150001, CHINA
7 shared publications - Pik Kwan Lo
Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon Tong, Hong Kong 999077, China
6 shared publications - Chuanqi Song
School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, China
4 shared publications - Ling Sum Liu
Department of Biology and Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, China
4 shared publications Tristan Juin Han Chang
Department of Chemistry and State Key Laboratory of Marine Pollution City University of Hong Kong Tat Chee Avenue Kowloon Hong Kong SAR P. R. China
4 shared publications- Wei Guo
Harbin Normal University
4 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in Med-X
- Vol. 4 (1) , 27
Innovative delivery strategies of bio-derived therapeutic agents for cardiac regeneration
- 13 November 2026
- Published by Springer Nature in Med-X
- Vol. 4 (1) , 27
Open AccessInnovative delivery strategies of bio-derived therapeutic agents for cardiac regeneration
- Open Access
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cardiac reprogramming via transient overexpression of P-glycoprotein alleviates doxorubicin-induced cardiotoxicity in mice and pigs
Doxorubicin-induced cardiotoxicity represents a significant clinical adverse effect associated with cancer chemotherapy treatment. Inspired by cancer drug resistance mechanisms, we propose a novel strategy termed transient overexpression of p-glycoprotein for cardiac reprogramming to induce cardiac drug resistance as a treatment for cardiotoxicity. This approach involves reprogramming cardiomyocytes by delivering lipid nanoparticles-based mRNA therapeutics to induce temporary p-glycoprotein overexpression, which in turn reduces intracellular doxorubicin levels and suppresses cytotoxic effects. This strategy results in promoted p-glycoprotein overexpression in cardiomyocytes, improved survival rates, restored cardiac function, and reduced myocardial fibrosis and structural cardiac alterations in a mouse model with doxorubicin-induced cardiotoxicity. Furthermore, studies in large animals show that intrapericardial injection of lipid nanoparticles with p-glycoprotein mRNAs effectively mitigates adverse effects and restores cardiac function in male pig models of doxorubicin-induced cardiotoxicity. The significant cardioprotective effects achieved through cardiac drug resistance highlight the safety, efficacy, and clinical potential of this strategy for alleviating doxorubicin-induced cardiotoxicity.
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCardiac reprogramming via transient overexpression of P-glycoprotein alleviates doxorubicin-induced cardiotoxicity in mice and pigs
Doxorubicin-induced cardiotoxicity represents a significant clinical adverse effect associated with cancer chemotherapy treatment. Inspired by cancer drug resistance mechanisms, we propose a novel strategy termed transient overexpression of p-glycoprotein for cardiac reprogramming to induce cardiac drug resistance as a treatment for cardiotoxicity. This approach involves reprogramming cardiomyocytes by delivering lipid nanoparticles-based mRNA therapeutics to induce temporary p-glycoprotein overexpression, which in turn reduces intracellular doxorubicin levels and suppresses cytotoxic effects. This strategy results in promoted p-glycoprotein overexpression in cardiomyocytes, improved survival rates, restored cardiac function, and reduced myocardial fibrosis and structural cardiac alterations in a mouse model with doxorubicin-induced cardiotoxicity. Furthermore, studies in large animals show that intrapericardial injection of lipid nanoparticles with p-glycoprotein mRNAs effectively mitigates adverse effects and restores cardiac function in male pig models of doxorubicin-induced cardiotoxicity. The significant cardioprotective effects achieved through cardiac drug resistance highlight the safety, efficacy, and clinical potential of this strategy for alleviating doxorubicin-induced cardiotoxicity.
- Open Access
- 23 May 2024
- Published by Wiley in Small Methods
- Vol. 8 (11) , e2400291
TNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy
Triple‐negative breast cancer (TNBC) remains a significant challenge in terms of treatment, with limited efficacy of chemotherapy due to side effects and acquired drug resistance. In this study, a threose nucleic acid (TNA)‐mediated antisense approach is employed to target therapeutic Akt genes for TNBC therapy. Specifically, two new TNA strands (anti‐Akt2 and anti‐Akt3) are designed and synthesized that specifically target Akt2 and Akt3 mRNAs. These TNAs exhibit exceptional enzymatic resistance, high specificity, enhance binding affinity with their target RNA molecules, and improve cellular uptake efficiency compared to natural nucleic acids. In both 2D and 3D TNBC cell models, the TNAs effectively inhibit the expression of their target mRNA and protein, surpassing the effects of scrambled TNAs. Moreover, when administered to TNBC‐bearing animals in combination with lipid nanoparticles, the targeted anti‐Akt TNAs lead to reduced tumor sizes and decreased target protein expression compared to control groups. Silencing the corresponding Akt genes also promotes apoptotic responses in TNBC and suppresses tumor cell proliferation in vivo. This study introduces a novel approach to TNBC therapy utilizing TNA polymers as antisense materials. Compared to conventional miRNA‐ and siRNA‐based treatments, the TNA system holds promise as a cost‐effective and scalable platform for TNBC treatment, owing to its remarkable enzymatic resistance, inexpensive synthetic reagents, and simple production procedures. It is anticipated that this TNA‐based polymeric system, which targets anti‐apoptotic proteins involved in breast tumor development and progression, can represent a significant advancement in the clinical development of effective antisense materials for TNBC, a cancer type that lacks effective targeted therapy.
- 23 May 2024
- Published by Wiley in Small Methods
- Vol. 8 (11) , e2400291
Open AccessTNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy
Triple‐negative breast cancer (TNBC) remains a significant challenge in terms of treatment, with limited efficacy of chemotherapy due to side effects and acquired drug resistance. In this study, a threose nucleic acid (TNA)‐mediated antisense approach is employed to target therapeutic Akt genes for TNBC therapy. Specifically, two new TNA strands (anti‐Akt2 and anti‐Akt3) are designed and synthesized that specifically target Akt2 and Akt3 mRNAs. These TNAs exhibit exceptional enzymatic resistance, high specificity, enhance binding affinity with their target RNA molecules, and improve cellular uptake efficiency compared to natural nucleic acids. In both 2D and 3D TNBC cell models, the TNAs effectively inhibit the expression of their target mRNA and protein, surpassing the effects of scrambled TNAs. Moreover, when administered to TNBC‐bearing animals in combination with lipid nanoparticles, the targeted anti‐Akt TNAs lead to reduced tumor sizes and decreased target protein expression compared to control groups. Silencing the corresponding Akt genes also promotes apoptotic responses in TNBC and suppresses tumor cell proliferation in vivo. This study introduces a novel approach to TNBC therapy utilizing TNA polymers as antisense materials. Compared to conventional miRNA‐ and siRNA‐based treatments, the TNA system holds promise as a cost‐effective and scalable platform for TNBC treatment, owing to its remarkable enzymatic resistance, inexpensive synthetic reagents, and simple production procedures. It is anticipated that this TNA‐based polymeric system, which targets anti‐apoptotic proteins involved in breast tumor development and progression, can represent a significant advancement in the clinical development of effective antisense materials for TNBC, a cancer type that lacks effective targeted therapy.
- 1 February 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 177, 472-485
Ultra-stable threose nucleic acid-based biosensors for rapid and sensitive nucleic acid detection and in vivo imaging
- 1 February 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 177, 472-485
Ultra-stable threose nucleic acid-based biosensors for rapid and sensitive nucleic acid detection and in vivo imaging
- 2 January 2021
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 13 (5) , 3184-3193
Targeted brain tumor imaging by using discrete biopolymer-coated nanodiamonds across the blood–brain barrier
Short circulation lifetime, poor blood–brain barrier (BBB) permeability and low targeting specificity limit nanovehicles from crossing the vascular barrier and reaching the tumor site. Consequently, the precise diagnosis of malignant brain tumors remains a great challenge. This study demonstrates the imaging of photostable biopolymer-coated nanodiamonds (NDs) with tumor targeting properties inside the brain. NDs are labeled with PEGylated denatured bovine serum albumin (BSA) and tumor vasculature targeting tripeptides RGD. The modified NDs show high colloidal stability in different buffer systems. Moreover, it is found that discrete dcBSA-PEG-NDs cross the in vitro BBB model more effectively than aggregated NDs. Importantly, compared with the non-targeting NDs, RGD-dcBSA-PEG-NDs can selectively target the tumor site in U-87 MG bearing mice after systemic injection. Overall, this discrete ND system enables efficacious brain tumor visualization with minimal toxicity to other major organs, and is worthy of further investigation into the applications as a unique platform for noninvasive theragnostics and/or thermometry at different stages of human diseases in the brain.
- 2 January 2021
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 13 (5) , 3184-3193
Targeted brain tumor imaging by using discrete biopolymer-coated nanodiamonds across the blood–brain barrier
Short circulation lifetime, poor blood–brain barrier (BBB) permeability and low targeting specificity limit nanovehicles from crossing the vascular barrier and reaching the tumor site. Consequently, the precise diagnosis of malignant brain tumors remains a great challenge. This study demonstrates the imaging of photostable biopolymer-coated nanodiamonds (NDs) with tumor targeting properties inside the brain. NDs are labeled with PEGylated denatured bovine serum albumin (BSA) and tumor vasculature targeting tripeptides RGD. The modified NDs show high colloidal stability in different buffer systems. Moreover, it is found that discrete dcBSA-PEG-NDs cross the in vitro BBB model more effectively than aggregated NDs. Importantly, compared with the non-targeting NDs, RGD-dcBSA-PEG-NDs can selectively target the tumor site in U-87 MG bearing mice after systemic injection. Overall, this discrete ND system enables efficacious brain tumor visualization with minimal toxicity to other major organs, and is worthy of further investigation into the applications as a unique platform for noninvasive theragnostics and/or thermometry at different stages of human diseases in the brain.
- 20 May 2020
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 12 (26) , 28928-28940
Penetrating the Blood–Brain Barrier by Self-Assembled 3D DNA Nanocages as Drug Delivery Vehicles for Brain Cancer Therapy
Development of biocompatible drug delivery vehicles for cancer therapy in brain remains a big challenge. In this study, self-assembled DNA nanocages functionalized with or without blood-brain barrier (BBB) targeting ligands were designed and investigated for BBB penetration. They showed no cytotoxicity, and substantial uptake in brain capillary endothelial cells and Uppsala 87 malignant glioma (U-87 MG) cells. It is found that ligand modification is not essential for this DNA system. The ligand-free DNA nanocages (LF-NCs) could still cross the BBB by endocytosis both in vitro and in vivo. These spherical DNA nanocages exhibited much better BBB permeability than tubular DNA nanotubes. Remarkably, in vivo studies revealed that DNA nanocages could carry the anticancer drugs across the BBB and inhibit the tumor growth in U-87 MG xenograft in nude mice. This is the first example showing the potential of DNA nanocages as innovative delivery vehicle in brain for cancer therapy. Unlike other delivery systems, our work suggests that DNA nanocage-based platform provides a safe and cost-effective tool for targeted delivery in brain and therapy of brain tumor.
- 20 May 2020
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 12 (26) , 28928-28940
Penetrating the Blood–Brain Barrier by Self-Assembled 3D DNA Nanocages as Drug Delivery Vehicles for Brain Cancer Therapy
Development of biocompatible drug delivery vehicles for cancer therapy in brain remains a big challenge. In this study, self-assembled DNA nanocages functionalized with or without blood-brain barrier (BBB) targeting ligands were designed and investigated for BBB penetration. They showed no cytotoxicity, and substantial uptake in brain capillary endothelial cells and Uppsala 87 malignant glioma (U-87 MG) cells. It is found that ligand modification is not essential for this DNA system. The ligand-free DNA nanocages (LF-NCs) could still cross the BBB by endocytosis both in vitro and in vivo. These spherical DNA nanocages exhibited much better BBB permeability than tubular DNA nanotubes. Remarkably, in vivo studies revealed that DNA nanocages could carry the anticancer drugs across the BBB and inhibit the tumor growth in U-87 MG xenograft in nude mice. This is the first example showing the potential of DNA nanocages as innovative delivery vehicle in brain for cancer therapy. Unlike other delivery systems, our work suggests that DNA nanocage-based platform provides a safe and cost-effective tool for targeted delivery in brain and therapy of brain tumor.
- 26 September 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (42) , 38510-38518
Synthetic α-l-Threose Nucleic Acids Targeting BcL-2 Show Gene Silencing and in Vivo Antitumor Activity for Cancer Therapy
We design and synthesize a sequence-defined TNA polymer which is complementary to the certain nucleotide site of target anti-apoptotic proteins BcL-2 involving in the development and progression of tumors. Comparing to the scramble TNA, anti-BcL-2 TNA significantly suppresses target mRNA and protein expression in cancerous cells and shows antitumor activity in carcinoma xenografts, resulting in suppression of tumor cell growth and induction of tumor cell death. Together with its good biocompatibility, very low toxicity, excellent specificity features and strong binding affinity towards the complementary target RNAs, TNAs become new useful biomaterials and effective alternatives to traditional antisense oligonucleotides including LNAs, MOs, and PNAs in antisense therapy. Comparing to the conventional cancer therapy such as radiotherapy, surgery and chemotherapy, we anticipate that this TNA-based polymeric system will work effectively in antisense cancer therapy and shortly start to play an important role in practical application.
- 26 September 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (42) , 38510-38518
Synthetic α-l-Threose Nucleic Acids Targeting BcL-2 Show Gene Silencing and in Vivo Antitumor Activity for Cancer Therapy
We design and synthesize a sequence-defined TNA polymer which is complementary to the certain nucleotide site of target anti-apoptotic proteins BcL-2 involving in the development and progression of tumors. Comparing to the scramble TNA, anti-BcL-2 TNA significantly suppresses target mRNA and protein expression in cancerous cells and shows antitumor activity in carcinoma xenografts, resulting in suppression of tumor cell growth and induction of tumor cell death. Together with its good biocompatibility, very low toxicity, excellent specificity features and strong binding affinity towards the complementary target RNAs, TNAs become new useful biomaterials and effective alternatives to traditional antisense oligonucleotides including LNAs, MOs, and PNAs in antisense therapy. Comparing to the conventional cancer therapy such as radiotherapy, surgery and chemotherapy, we anticipate that this TNA-based polymeric system will work effectively in antisense cancer therapy and shortly start to play an important role in practical application.
- 20 August 2019
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 43 (36) , 14443-14449
Conjugated polymer dots for biocompatible siRNA delivery
Small interfering RNA (siRNA) that mediates target gene silencing through RNA interference (RNAi) has attracted increasing interest in exploring gene functions as well as treating a variety of diseases. However, the inefficient delivery of the unstable and negatively charged siRNA into cells restricts the progress of the RNAi-based therapeutics. In this work, we describe the development of a nanoplatform based on conjugated polymer dots (Pdots) for efficient siRNA delivery. The cationic lipid G0C14 was introduced in the Pdots for siRNA complexing. The G0C14-containing polymer dots (G-Pdots) not only retained the outstanding fluorescence properties but also enhanced cellular uptake of siRNA. The positively charged G0C14 was able to interact with the negatively charged siRNA via electrostatic interactions, while the G-Pdot/siRNA complexes still remained negatively charged. A prominent property of this nanoplatform was the low cytotoxicity as compared to the commercial agent Lipofectamine, while the gene silencing efficiency was comparable. Our results indicate that biocompatible G-Pdots represent a promising platform for imaging-guided siRNA delivery.
- 20 August 2019
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 43 (36) , 14443-14449
Conjugated polymer dots for biocompatible siRNA delivery
Small interfering RNA (siRNA) that mediates target gene silencing through RNA interference (RNAi) has attracted increasing interest in exploring gene functions as well as treating a variety of diseases. However, the inefficient delivery of the unstable and negatively charged siRNA into cells restricts the progress of the RNAi-based therapeutics. In this work, we describe the development of a nanoplatform based on conjugated polymer dots (Pdots) for efficient siRNA delivery. The cationic lipid G0C14 was introduced in the Pdots for siRNA complexing. The G0C14-containing polymer dots (G-Pdots) not only retained the outstanding fluorescence properties but also enhanced cellular uptake of siRNA. The positively charged G0C14 was able to interact with the negatively charged siRNA via electrostatic interactions, while the G-Pdot/siRNA complexes still remained negatively charged. A prominent property of this nanoplatform was the low cytotoxicity as compared to the commercial agent Lipofectamine, while the gene silencing efficiency was comparable. Our results indicate that biocompatible G-Pdots represent a promising platform for imaging-guided siRNA delivery.
- 9 April 2019
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 7 (7) , 2729-2739
The theranostic nanoagent Mo2C for multi-modal imaging-guided cancer synergistic phototherapy
Mo2C is an excellent photoactive material that can trigger hyperthermia and ROS generation, thus contributing to synergistic photothermal/photodynamic outcomes. Moreover, Mo2C is a potential photoacoustic and CT contrast agent.
- 9 April 2019
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 7 (7) , 2729-2739
The theranostic nanoagent Mo2C for multi-modal imaging-guided cancer synergistic phototherapy
Mo2C is an excellent photoactive material that can trigger hyperthermia and ROS generation, thus contributing to synergistic photothermal/photodynamic outcomes. Moreover, Mo2C is a potential photoacoustic and CT contrast agent.
- 21 February 2019
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 91 (6) , 4179-4185
Cooperative Blinking from Dye Ensemble Activated by Energy Transfer for Super-resolution Cellular Imaging
Photoblinking is a fundamental process that occurs exclusively in single fluorophores such as organic dyes, fluorescent proteins, and quantum dots. Here, we describe a strategy to achieve pronounced, high on/off ratio, and cooperative blinking in donor-acceptor multi-fluorophore systems. An ensemble of dye molecules doped in semiconducting polymer dots (Pdots) exhibit robust photoblinking, while the pristine Pdots and the dye in optically-inert polymer matrices fluoresce continuously. Energy transfer from Pdots to dye acceptors produces photoblinking via a cooperative process, in which the bright state originates from the dye ensemble and the dark state is due to quenching of semiconducting polymer by hole polarons. Using the blinking Pdots in subcellular structures labeling, we demonstrated approximately 3.6-fold enhancement of imaging resolution in high-order super-resolution optical fluctuation nanoscopy as compared to conventional microscopy. Our findings not only demonstrate the exciting possibility of transforming a non-quantized ensemble into a single-emitter-like optical source, but also provide an effective approach to generate superior photoblinking fluorescent probes for super-resolution imaging applications.
- 21 February 2019
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 91 (6) , 4179-4185
Cooperative Blinking from Dye Ensemble Activated by Energy Transfer for Super-resolution Cellular Imaging
Photoblinking is a fundamental process that occurs exclusively in single fluorophores such as organic dyes, fluorescent proteins, and quantum dots. Here, we describe a strategy to achieve pronounced, high on/off ratio, and cooperative blinking in donor-acceptor multi-fluorophore systems. An ensemble of dye molecules doped in semiconducting polymer dots (Pdots) exhibit robust photoblinking, while the pristine Pdots and the dye in optically-inert polymer matrices fluoresce continuously. Energy transfer from Pdots to dye acceptors produces photoblinking via a cooperative process, in which the bright state originates from the dye ensemble and the dark state is due to quenching of semiconducting polymer by hole polarons. Using the blinking Pdots in subcellular structures labeling, we demonstrated approximately 3.6-fold enhancement of imaging resolution in high-order super-resolution optical fluctuation nanoscopy as compared to conventional microscopy. Our findings not only demonstrate the exciting possibility of transforming a non-quantized ensemble into a single-emitter-like optical source, but also provide an effective approach to generate superior photoblinking fluorescent probes for super-resolution imaging applications.